Comparative Pharmacology
Head-to-head clinical analysis: AIMOVIG versus UBRELVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIMOVIG versus UBRELVY.
AIMOVIG vs UBRELVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIMOVIG (erenumab) is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. CGRP is a neuropeptide involved in the pathophysiology of migraine; its release leads to vasodilation and activation of pain pathways.
Calcitonin gene-related peptide (CGRP) receptor antagonist; blocks CGRP-mediated vasodilation and nociception.
70 mg subcutaneously once monthly; some patients may benefit from 140 mg subcutaneously once monthly.
100 mg orally once, may repeat once after at least 2 hours if needed; maximum 200 mg per 24 hours.
None Documented
None Documented
28 days (range 23-31 days) in healthy volunteers; supports monthly subcutaneous dosing.
Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing.
Elimination via proteolytic catabolism; no renal or biliary excretion of intact antibody.
Primarily hepatic metabolism via CYP3A4, with 42% of dose excreted in feces (6% unchanged) and 26% in urine (1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist